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 1 
Abstract 
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in 
the United States and more than 610,000 people die every year from ASCVD related causes such 
as myocardial infarction (MI) or stroke. High cholesterol is one of the leading modifiable risk 
factors for prevention of ASCVD events. The 2013 American College of Cardiology/American 
Heart Association guidelines recommend treatment of high cholesterol as primary prevention for 
ASCVD in adults by lifestyle changes, CV risk estimation with an ASCVD calculator, and 
intensity dosing of statin medication. Effective strategies to support these recommendation exist 
in the clinical practice guidelines but evidence suggest use of the ASCVD calculator for risk 
estimation and statin intensity dosing in primary care is not being implemented by primary care 
practitioners (PCP) consistently.  
Purpose:  The purpose of this study was to evaluate current hyperlipidemia practices in a Norton 
Medical Associates Clinic (NMA) to establish baseline use of educational material, 
cardiovascular risk estimate with an ASCVD calculator, and statin prescribing methods.  
Methods:  In this descriptive study utilizing a retrospective chart review, 300 charts from NMA 
were randomly selected and reviewed for documentation of 1) serum total cholesterol and LDL-c 
levels, 2) statin medication and dosage prescribed, 3) the intensity of the statin dosage, 4) 
ASCVD risk factors, and 5) 10 year CV risk estimation. This project evaluated patients between 
the ages of 21 and 75 with an active diagnosis of high cholesterol and those that met the 
requirement for statin therapy according to the 2013ACC/AHA guidelines.  
Results:  According to the results of this review 36% of patients with high cholesterol were not 
receiving the recommended statin therapy supported by the 2013-guideline grade A or B 
recommendations. In the three subgroups of patients with dyslipidemia (high risk, moderate risk, 
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diabetes mellitus (DM), 6 out of 7 patients (86%) in the high-risk group (LDL-c>190) were on 
the correct type and dosage of a high intensity statin medication.  In the moderate risk group 
(LDL-c 70-189) only 65% were receiving statin therapy. The most concerning result from this 
study is the moderate risk patient category, where 35% were not receiving any statin therapy 
when they should have been on at least a moderate intensity statin medication and no ASCVD 
risk estimate was calculated.  
Conclusion:  Based on the results from this chart review there is room for improvement for 
PCPs in the treatment and evaluation of hyperlipidemia patients for primary prevention of 
ASCVD. This paper will discuss evidence based practice recommendations and suggestions for 
further investigation. 
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Evaluation of Treatment for High Cholesterol and Prevention of Cardiovascular Disease in 
Primary Care 
Background and Significance 
Atherosclerotic cardiovascular disease (ASCVD) accounts for more deaths annually than 
any other disease process with an estimated 17 million deaths in 2008 and a projected 23.3 
million deaths by 2030.  Thirty percent of deaths in Kentucky are related to CV disease 
(myocardial infarction and strokes) placing Kentucky above the national average for CV deaths 
in 2009 (Kentucky Heart Foundation [KYGOV], 2012).  High cholesterol is one of the leading 
modifiable risk factors for heart disease and stroke (American Heart Association, 2014). One of 
the leading health indicators proposed in Healthy People 2020 was to improve ASCVD 
awareness and prevention by increased screening (Office of Disease Prevention and Health 
Promotion [HP2020], 2014. Adherence to a healthy lifestyle and statin medication for patients 
with high cholesterol can reduce development of CV disease (Office of Disease Prevention and 
Health Promotion [ODPHP], 2014).  
Recommendations from the ACC/AHA 2013 Guidelines on the Treatment of High 
Cholesterol to Reduce Atherosclerotic Cardiovascular Disease in Adults support PCPs in the 
treatment and management of high cholesterol to reduce the risk of coronary artery disease, heart 
attack, and stroke (American Heart Association, 2014). High cholesterol is a modifiable risk 
factor that can be controlled with appropriate doses of statin therapy and lifestyle changes (Stone 
et al., 2013).   According to Stone (2013), statin therapy is divided into three medication groups: 
high intensity, moderate intensity and low intensity (see Table 1).  Intensity dosing of statin 
medication is based on individual CV risk and elevated serum LDL cholesterol levels.  The 
guideline categorizes individuals into four major statin benefit groups:  1) diagnosed with 
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ASCVD, 2) primary elevation of LDL-c >190, 3) diabetes age 40-75 with LDLc 70-189, and 4) 
no ASCVD or DM and LDLc 70-189.  
Recommendations for cholesterol treatment prior to the 2013 guidelines focused on 
treating high cholesterol with statin therapy and decreasing serum cholesterol numbers to a 
normal range, treat to target (Stone et al., 2013). The current 2013 guidelines shift from 
treatment solely on LDL-c target levels to a focus on reducing LDL-c levels by 30-50% and 
decreasing the risk of developing ASCVD with statin therapy and lifestyle changes (Sherrod et 
al., 2015). Historically PCPs have been focused on decreasing serum LDL-c levels with statin 
therapy. Morris et al. (2014) recommend that providers also focus on decreasing an individual’s 
ASCVD risk estimates with the decrease in LDL-c. 
To more accurately guide the PCP in identifying high risk individuals for statin therapy, 
the ASCVD calculator from the guideline noted as Pooled Cohorts Equations, recommend 
estimation of 10-year ASCVD risk in both white and black men and women who do not have 
ASCVD (Stone et al., 2013). The screening goals for primary prevention of CV disease are based 
on the recommendations of the 2013 AHA/ACC guideline that has been compacted into a one-
page algorithm to guide PCPs in cholesterol management (see Figure 1).  The ASCVD lifetime 
risk calculator is based on the Framingham Risk Score (FRS) and used mainly for those 
individuals categorized into the 4th statin benefit group, those aged 40-75 with LDL-c levels of 
70-189, no DM, no ASCVD, LDL-c 70-189 (Stone et al., 2013).  The guideline objectives are to 
achieve measurable improvements for individuals with hyperlipidemia, up to a 50% decrease in 
LDL-c, by maintaining a healthy lifestyle and adhere to the appropriate intensity statin 
medication therapy (Stone et al., 2013).  
 
 5 
Strategies for ASCVD Prevention 
Lifestyle Modifications 
A critical review of the literature found the most effective strategies for primary 
prevention of ASCVD to be lifestyle changes and statin therapy (Fabregas et al., 2014; Lopez-
Jimenez et al., 2014; McMonnachie et al., 2014; Morris, Ballantyne, Birtcher, Dunn, & Urbina, 
2014; Persell, Lloyd-Jones, Frieseman, Cooper, & Baker, 2013; Sekaran, Sussman, Xu, & 
Hayword, 2013; Stone et al., 2013).  ASCVD is a national healthcare problem where obesity, 
diabetes, hypertension, and hyperlipidemia are major contributing factors (Fabregas et al., 2014). 
Lifestyle changes such as exercise, diet, and medication adherence are effective prevention steps 
for ASCVD.  Diet modifications that lower LDL-c consist of fruits, vegetables, low fat dairy, 
and lean meat products (Sherrod, Sherrod, & Cheek, 2015).  Daily cardiovascular exercise for 
more than 40 minutes and maintaining a BMI<24 are recommended (Stone et al., 2013).  For 
treatment of familial hyperlipidemia high intensity statin therapy and lifestyle modifications 
were found to be the most significant factor in preventative treatment (Broekhuizen et al., 2012). 
ASCVD Risk Estimate 
The 2013 AHA/ACC guideline recommends the use of the 10-year ASCVD risk 
calculator when prescribing statin therapy (Stone et al., 2013). The guideline encompasses 
several ranges of cholesterol management based on the age and estimated risk calculation of the 
patient by targeting patients with known ASCVD. The use of this calculator has been shown to 
improve prescribing accuracy for providers and decrease discrepancies in estimating the 
appropriate statin dose based on the estimated risk percentage (Sekaran et al., 2013). A patient 
with 10-year cardiovascular risk >7.5% and elevated LDL-c cholesterol should receive a high 
intensity statin medication (Stone et al., 2013). Studies supporting the use of a 10-year risk 
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calculator reported significant differences in PCPs treatment for statin therapy; using the risk 
calculator significantly increased prescribing strategies in high-risk individual and decreased 
prescribing strategies in low risk cases (Sekaran et al., 2013).  
Statin Therapy 
Overall nearly one-third of global mortality is attributed to ASCVD, however, lipid-
lowering therapy with statin medications has been shown to decrease LDL-c by 55% (Lardizabal 
& Deedwana, 2011).  The reduction in LDL-c and improvement in elevated lipids associated 
with stain therapy has been shown to substantially reduce mild and moderate coronary artery 
lesions developed from plaque ruptures resulting in myocardial events (Lardizabal & Deedwana, 
2011).  Decrease in arterial plaque size after statin treatment has resulted in significant 
improvement in patient outcomes after statin treatment (Tian et al., 2012).  Statin therapy has 
shown a significant clinical benefit in lipid lowering therapy in primary prevention ASCVD in 
numerous randomized controlled trials and a decrease in mortality rates between 1-5% (Lewis, 
2011) 
Long-term statin therapy, greater than five years, has shown benefit by reducing ASCVD 
events such as myocardial infarction, stroke, and heart failure (McMonnachie et al., 2014).  A 
reduction of first hospital admission for an ASCVD event and recurrent events were substantially 
reduced with appropriate statin treatment (McMonnachie et al., 2014). A recent study by 
McConnachie (2014) found significant improvements in decreasing length of stay (LOS) and 
quality-adjusted life years (QALY) in patients who had been on statin therapy longer than five 
years.  High intensity statin therapy resulted in decreased hospital length of stay (LOS), however 
the PCPs did not always calculate cardiovascular risk estimation and utilization of statin therapy 
did not always follow recommendation guidelines (McMonnachie et al., 2014).  
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Education on ASCVD Risk 
To guide evidence based treatment, a 10-year ASCVD risk calculator was shown to be an 
effective tool for primary care practitioners in accurate dosing of statin therapy and an 
educational tool for patients with a >7.5% lifetime risk for an ASCVD event (Allen, Garrison, & 
McCormack, 2014; Krones et al., 2008; Morris, Ballantyne, Birtcher, Dunn, & Urbina, 2014; 
Sekaran, Sussman, Xu, & Hayword, 2013;). The10-year CV risk calculator may also be utilized 
to expand provider documentation in the electronic medical record systems as a tool for 
screening ASCVD risk, education on individual risk, and promote accurate calculation for statin 
medication therapy (Sekaran et al., 2013).  Education by motivational interviewing also has been 
used to increased accuracy in proper prescribing of statin therapy by PCPs and primary 
prevention screening by PCPs (Persell et al., 2013). 
Purpose 
 The purpose of this project was to evaluate current practices among PCPs in the NMA 
clinics related to treatment of high cholesterol with statin therapy. Based on the 2013 ACC/AHA 
guideline recommendations for treatment of high cholesterol, screening methods for primary 
prevention are to include screening for cardiovascular risk factors, lifetime 10-year ASCVD risk 
for a cardiovascular event, and statin therapy (Stone et al., 2013). Review of these factors will 
help facilitate providers in reaching medical statin therapy goals and current screening processes 
for hyperlipidemia. Evaluation of the current hyperlipidemia practices can provide Norton 
Healthcare baseline quality improvement data for future studies in primary prevention of 
ASCVD in Kentucky.  
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Methods 
Design 
A descriptive study utilizing a retrospective chart review of 300 patients assessed the 
current practices of NMA clinic PCPs on prescribing statin therapy medication and 
documentation of ASCVD risk.  Patients included in this review were between the age of 21 and 
75 and diagnosed with ICD9 and ICD10 codes for high cholesterol, hyperlipidemia, or 
dyslipidemia. The charts were reviewed for serum total cholesterol and LDL-c levels, statin 
medication and dosage prescribed, categorized as moderate or high intensity statin, and 
documentation of cardiovascular risk from 2014, 2015, and 2016.  Patients with high cholesterol 
and a diagnosis of diabetes mellitus (DM) were excluded in the review because they have risk 
factors similar to those in the secondary prevention group.  The chart review was conducted from 
the EPIC electronic medical record system (EMS).  IRB approval was obtained through 
University of Kentucky and Norton Healthcare. 
Sample 
 For this retrospective chart audit review two of the four statin target groups from the 
guideline were used. In order to focus on primary prevention of CV disease, patients diagnosed 
with ASCVD were excluded.  The two groups were selected because they focused on primary 
prevention and received a Grade A or B recommendation for practice from National Heart, Lung, 
and Blood Institute (Stone et al., 2013). The three areas are:  
A.  For >21 years with LDLc >190 
 1. High intensity statin therapy (B) 
 2. Highest does statin tolerated for those with intolerance to high intensity (B) 
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B. For 40-75, no DM and LDLc 70-189 and CV risk >7.5% 
 1. Moderate to high intensity statin (A; Stone et al., 2013) 
Data Collection 
One hundred patients from each year (2014-2016) were randomly selected and pertinent 
information from each chart was logged into an chart audit tool (see Appendix A) and include 
the following variables, age, sex, race, ethnicity, BMI, serum total cholesterol, LDL-c, CV risk, 
CV event, statin medication and dosage, DM, and contraindications to statin medications.  The 
statin medication prescribed was included as well as an indicator variable, categorized as 
moderate or high intensity statin therapy based on the 2013 guidelines (see Appendix B).  
There were three areas of the chart that were reviewed for documentation of ASCVD risk 
1) the subjective area (history of present illness), 2) the plan, and 3) the visit summary. ASCVD 
risk was defined as PCP-documented patient education on the effects of high cholesterol or 
ASCVD or calculation and documentation of lifetime 10-year ASCVD risk estimate percentage. 
Patients with a CV event (MI, stroke, or CAD) were excluded from the analysis because they 
were categorized as secondary prevention candidates.  
Data Analysis 
Data was analyzed using the IBM Statistical Package for the Social Sciences (SPSS) v 22 
software.  Descriptive statistics were used to summarize patient demographics, CV risk 
documentation, and the adherence to prescribed statin therapy by PCPs to 2013 guideline 
recommendations.   
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Results 
Of the patients reviewed, 203 of the 300 met the inclusion criteria for this review whereas 
92 were either >75years of age, did not have a serum LDL-c recorded, and 5 had 
contraindications to statin therapy. The population sample was mostly Caucasian (90.6%) with 
9.4% listed as other. The mean age of the patients was 57.9, with the youngest at 22 years and 
the max age of 70.  This was a mostly obese population with the mean BMI of 31.6 that ranged 
from 19-54 (see Table 2).  
Across all three hyperlipidemia categories, three-quarters (76%) of patients were on statin 
therapy.  The percentage of patients that were on the correct statin therapy based on the 2013 
guideline was 64% and 36% of the hyperlipidemia patients were not receiving the appropriate 
statin therapy. Eighty-two percent of the patients reviewed did not have documentation of 
cardiovascular risk factors such as hypertension, smoking, elevated BMI, or DM on the plan or 
visit summary and none of the charts reviewed had documentation for lifetime 10-year 
cardiovascular risk % estimate. 
Of the 203 patients reviewed 7 were in the high-risk category, 119 were in the moderate 
risk category, and 74 were diabetic.  Of the seven in the high-risk category, having an LDL-c 
>190mg/dL, six of them (85%) were prescribed the appropriate high intensity. Notably, of the 
119 patients in the moderate risk category (without DM or CVD and LDLc between 70-189), 47 
(35%) were not receiving statin medication (see Table 3). According to the 2013 guidelines an 
ASCVD risk estimate be calculated to accurately dose statin therapy for patients in the moderate 
risk category. None of the moderate risk category patients had ASCVD risk calculation.  
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Discussion 
According to the results of this review 36% of patients with high cholesterol are not 
receiving the recommended statin therapy supported by the 2013-guideline recommendations 
(see Table 3).  This chart review showed that 82% of the time ASCVD risk factors such as 
family history of heart disease, hypertension, BMI, and smoking were not documented in the 
SOAP notes and no 10-year CV risk estimate was documented for any patient in the evaluation 
of statin therapy prescribing. Evidence has shown improved accuracy by PCPs in statin 
prescribing in each focus area (high risk and moderate risk) with the use of the ASCVD risk 
estimation (Stone et al., 2013). 
Six out of seven patients (86%) in the high-risk group (LDL-c>190) were on the correct 
type and dosage of a high intensity statin medication. The guideline clearly states all high-risk 
category patients need high intensity statin therapy, regardless of ASCVD risk estimate (Stone et 
al., 2013) unless there is intolerance of statin medications such as muscle pain, elevated liver 
enzymes, or allergic reactions (Stone et al., 2013). Although no documentation of these negative 
effects were not noted in this chart, not all education or discussion at a patient visit is included in 
the visit documentation.   
Among the moderate risk group (LDL-c 70-189) only 60.5% were receiving statin 
therapy. The most concerning result from this study is the moderate risk patient category, where 
39.5% were not receiving any statin therapy and no ASCVD risk estimate was calculated as 
recommended in the 2013 guidelines.  Despite recent publications on the ASCVD risk factors 
and risk estimation for patients with high cholesterol, there are an inadequate number of patients 
receiving appropriate standard lipid lowering therapy across the primary care setting (Morris et 
al., 2014).  Factors contributing to this gap in delivering evidence based care include confusion 
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in guideline implementation for lipid management and lack of LDL-c related risk estimation by 
providers (Morris et al., 2014).  
If providers consistently followed the clinical practice guidelines, evidence suggests that 
the effect would show a 30-50 % decrease in LDL-c and a comparable decrease in total 
cholesterol levels (Stone et al., 2013). For each 39mg/dL reduction in LDL-c with statin therapy 
ASCVD risk decreases 20% (Sherrod et al., 2015).  Notably, with a 30-50% decrease LDL-c the 
10-year ASCVD estimated risk with a risk calculator would show a comparable decrease of 30-
50% in lifetime risk.  For patients with high cholesterol the documentation of the 10-year 
ASCVD risk estimate could be compared at each visit for improvements in lifestyle behaviors 
and medical adherence (Sherrod et al., 2015). 
Norton Medical Associates providers are not currently documenting CVD risk 
calculation, however, with implementation of an ASDVD risk calculator in the EMR 
documentation could be more consistent. For example, Allen and colleagues (2013) found that 
only 22%-48% of PCPs regularly use risk assessment tools to determine ASCVD risk for 
patients with high cholesterol (Allen et al., 2013).  PCPs subjective estimation of risk without use 
of a risk calculator is found to be congruent with risk estimation with a calculator approximately 
60% of the time (Allen et al., 2013). This reflects the evidence found in this chart review where 
60.5% of the patients are receiving the correct statin dosage but 39.5% are not.   
Documentation of the risk estimate for Norton PCPs could not only improve statin 
prescribing and decrease CV risk for the 39.5% of the patients in the clinical area not receiving 
the appropriate statin therapy but could increase patient outcome measures between visits and 
interdisciplinary teams. Documentation of the lifetime risk in the EMR allows PCPs an 
opportunity to initiate education and monitor patient outcomes at each visit. Acceptance and 
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adaptation of the clinical guidelines in practice is essential to the evaluation and treatment of 
hyperlipidemia and the appropriate statin medication (Parker et al., 2008).  
Evidence supports using a 10-year risk calculator as a starting point for PCP and patient 
dialogue (Martin et al., 2015) Use of the ASCVD risk assessment between clinician and patient 
has been shown as an interventional tool to initiate and encourage discussions for patient lifestyle 
changes (Martin et al., 2015).  Patient education about ASCVD risk and primary prevention 
using a 10-year CV calculator by PCPs has been shown to improve prescribing accuracy for 
PCPs for statin medications (Fabregas et al., 2014). ASCVD risk assessment in primary care and 
patient education can lead to an increase in patients adherence to medication therapy and lifestyle 
changes (Persell et al., 2013).  
Barriers to Implementation 
Potential barriers for PCPs for complete application of the new guidelines 
recommendation into their practice include, delayed adaptation of the new recommendations, 
time constraints, and the complexity of the guideline (Martin et al., 2015; Parker et al., 2008). 
High intensity statin therapy is associated with more frequent side effects and PCPs are less 
likely to initially prescribe high intensity statin therapy for the patients in the high-risk group, 
LDL-c >190 (Ahn et al., 2016). Fear of side effects such as myalgias and rhabdomyolysis, 
decrease patient adherence with statin therapy and prevent high intensity statin prescribing by 
PCPs (Virani et al., 2014).  Notably, some physicians delay treatment with statin therapy, in the 
moderate risk group, to allow patients time to make lifestyle modification changes first to 
decrease cholesterol (Ahn et al., 2016).  In order for screening methods to be effective for 
primary prevention of ASCVD, therapeutic interventions with statin medications must be 
initiated as early treatment (Ahn et al., 2016).  
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Variability in the use of different styles of risk calculators has been established in the 
literature.  Recent studies have shown limitations in accuracy and fluctuation of risk percentage 
calculation of ASCVD risk based on the type of risk calculator selected and the epidemiology of 
the patient population (Allen et al., 2013). The margin of error for risk calculators is low and 
inconsistency is due to differing databases, combinations of ASCVD end points and 
mathematical algorithms for individual databases (Allen et al., 2013).  Most of the absolute risk 
estimate variability was in the high-risk ASCVD patients over 65 years of age.  Organizational 
selection of a risk calculator should reflect characteristics of the patient population.  
Recent studies show that most PCPs agreed on the outcomes from the Framingham Risk 
Calculator (FRC) 90% of the time (Allen et al., 2013). The 2013 guideline Pooled Cohorts 
supports an ASCVD calculator, which is based on the FRC (Stone et al., 2013). Notably, PCP 
barriers to the implementation of risk calculation were time, the sense of over simplification with 
the risk tools, and an ability to predict risk subjectively (Allen et al., 2013). However, research 
has shown that 40% of PCPs struggle to accurately estimate absolute risk without use of risk 
estimation tools (Allen et al., 2013). 
Limitations 
One reason for the lack of documentation of risk factors could be because use of the 
ASCVD calculator by PCPs for risk estimate and assessment could be occurring for NMA clinics 
at each visit but not documented in the EMR. Also documentation of these risk factors could 
have been in previous chart occurrences and reviewed by the provider at the time of the visit. 
There was an increase in documentation of education on high cholesterol and ASCVD risk from 
the review of charts in 2014 compared to 2016; Zero in 2014 and 10 in 2016. This improvement 
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could have been a result of increased educational information in the EMR instead of recognition 
of the 2013 guideline recommendations.  
Implications for Practice 
 Despite the limitations of this study an important recommendation for this practice site is 
to implement the ASCVD risk calculator into the EMR. Calculation of ASCVD risk estimation 
improves PCPs prescribing of statin therapy (Sekaran et al., 2013).  
With implementation of the risk calculator in the EMR, estimated risk will be 
immediately available to the patient and PCP. The calculator will also assist the PCPs in the 
education on ASCVD and accurate prescribing of statin therapy. For the moderate risk patient 
the guidelines recommend statin therapy for patients with a CV risk >7.5% or estimated risk 5-
7.4% (Stone et al., 2013). Quality improvement monitoring for the documentation of estimated 
lifetime risk in the patients chart is one way to evaluate adherence of provider participation with 
the risk calculation and medication prescribing.   
 Evaluation of current hyperlipidemia reduction practices in the NMA clinics can assist 
providers in reaching medical therapy goals and improving patient education on cardiovascular 
risk. Strategies to improve the accuracy of statin prescribing could be developed by auto 
calculation and flagging ASCVD risk in the EMR. The calculator has been shown to improve 
statin prescribing accuracy by providers for patient with high cholesterol (Persell et al., 2013).  
Use of the calculator as a primary prevention tool has been shown as a starting point for 
provider-patient education about estimated life risk and changes in lifestyle habits to promote a 
healthy lifestyle (Martin et al., 2015).   
ASCVD risk estimation provides the PCP with individual patient risk and visual aids can 
improve patient understanding and satisfaction (Martin et al., 2015).  Documented risk at each 
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visit can be graphically projected in the patients chart to be used as evaluation of progress or 
regression by the patient and the provider.  The EMR system optimizes opportunity for patient 
and provider communication by personalization of information and dispersing educational 
information (Fabregas et al., 2014). Currently in the Norton system the EMR is used to present 
graphical data showing changes in BMI, blood pressure, hemoglobin A1C, and cholesterol.  Use 
of this graphical system to show 10-year ASCVD risk could be useful to the PCP and the patient 
to improve education and statin adherence. Use of the EMR for messaging patients about their 
ASCVD risk has shown to improve lipid-lowering prescribing of statin medications (Persell et 
al., 2013).  
 Auto calculation of 10-year ASCVD risk estimation at each patient visit in the EMR 
would allow PCPs quicker access to patient risk and comparison of patient outcomes.  The risk 
estimation can be auto calculated and located in the subjective section of the chart in order for 
PCPs easily identify patients at high risk and to initiate discussion for plan of care. With EMR 
availability, the automation of ASCVD risk calculation and education on risk factors at each 
patient visit could improve ASCVD screening (Cainzos-Achirica, Eissler, Blaha, Blumenthal, & 
Martin, 2015).  Easy access to the risk estimation can improve education on cardiovascular risk 
and accuracy in statin dosing (Parker et al., 2008).  
 Basic ASCVD risk estimation with a calculator is an easy starting point to improve 
accuracy of prescribing statin therapy and education for patients in primary care with 
hyperlipidemia. Biomarkers, CRP, and noninvasive testing are also key factors in managing 
treatment for hyperlipidemia and dyslipidemia patients (Stone et al., 2013).  Treatment plans 
must be individualized and more invasive and expensive options are available such as coronary 
artery calcium imaging (CAC), serum biomarkers, and the use of radiographic imaging such as 
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computed tomographic scanning (Cainzos-Achirica, Eissler, Blaha, Blumenthal, & Martin, 
2015).   
Conclusion 
 PCPs can use tools from the 2013 ACC/AHA guidelines in practice to improve screening, 
education, statin therapy prescribing, and to ultimately decrease the risk of CV deaths among 
patients with high cholesterol. Using a combination of the algorithm from the 2013 guidelines 
for prescribing statin therapy, 10-year CV risk estimate, and education on lifestyle changes in 
clinical practice can improve medication accuracy and primary prevention screening in primary 
care. Implementation of automatic calculation of 10-year risk within the EMR could decrease 
time barriers, increase ease of accessibility and promote accurate documentation of ASCVD risk. 
Introducing the CV risk calculator into primary practice by auto calculation for all 
patients with the diagnosis of hyperlipidemia in the EMR gives PCPs quick and easy access to 
risk estimation and graphical visuals for patient education.  Documentation of ASCVD in a 
specified location allows quality improvements in statin prescribing and patient outcomes to be 
easily accessible in the EMR.  Improvement in screening and treatment in primary care based on 
the recommendations from the 2013 guideline for patients with high cholesterol will ultimately 
decrease morbidity and mortality in Kentucky. 
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Table 1 
2013 Guideline Recommended Statin Medication Intensity  
 
Intensity dosing of statin Medication 
High Intensity Moderate Intensity Low Intensity 
Daily dosage lowers LDL-c by 
approximately >50% on 
average 
Daily dosage lowers LDL-c by 
approximately 30%-50% on 
average 
Daily dosage lowers LDL-c 
<30% on average 
Atorvastatin 40-80 mg Atorvastatin 10mg Simvastatin 10 mg 
Rosuvastatin 20mg Rosuvastatin 20-40 mg Pravastatin 10-20mg 
 Simvastatin 20-40 mg Lovastatin 20mg 
 Pravastatin 40mg Fluvastatin 20-40mg 
 Lovastatin 40mg Pitavastatin 1 mg 
 Fluvastatin XL 80mg  
 Pitavastatin 2-4 mg  
   
 
(Stone et al., 2013, p. 17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 24 
 
Table 2 
Demographic characteristics of study patients 
 
 Number of 
Patients N=203 
Percent 
Population Minimum Maximum Mean 
Age 
  22 74 58 
BMI 
  19 54 32 
Gender      
Male  
95 46.8%    
Female 
108 53.2%    
Ethnicity 
     
Caucasian 
184 91.1%    
Asian 1 0.5%    
African American 16 7.9%    
Hispanic 
1 0.5%    
Other 
1 0.5%    
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Table 3 
Descriptive Statistics 
Percentage of Patients receiving the appropriate dose statin medication 
 Number of Patients Percent 
Patients NOT on Recommended  
Statin Therapy 74 36.5% 
Patients on Recommended 
Dosage  
of Statin Therapy 
129 63.5% 
Total 203 100 
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Table 4 
Descriptive statistics on Statin Population 
 
Statin Therapy Review Population 
Patient Population 
Total 
Patients per 
group 
No statin 
Therapy 
High 
Intensity 
Statin 
Moderate 
Intensity 
Statin 
Percentage 
on Statin 
Therapy 
LDL-c >190mg/dL 
High Intensity Statin 7 1 6 0 86% 
LDL-c 70-189mg/dL* 
Moderate or High Intensity Statin 
Based on ASCVD risk >7.5% 
119 47 4 68 60.5% 
Total Population 126 48 10 68  
 
     
*No DM, No ASCVD 
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 Appendix A 
Chart Audit Tool 
   
       
Evaluation of Lipid Blood Levels, Statin Medication and Dosage, BMI, Cardiovascular Risk Documentation 
         
         
Study Number:        
Age (21-75):        
    Statin dosage  Statin Medication BMI CV Risk 
Documentation 
CV risk 
>7.5% 
LDL>145 Y/N       Y/N   
LDL>190 Y/N       Y/N   
              
         
Information:              
Was the appropriate Medication prescribed:      
         
Was the appropriate dosage prescribed:   
 
  
        
Were there contraindications for this patient for statin therapy: Y/N Describe:   
      
 
  
        
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	   	   	   	   	   	  
 28 
   Appendix B 
Guideline Algorithm 
 
 
(Stone et al., 2013, p. 12) 
 
 
 
 
 
 
 
 
 
Yes
Age <75 y
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)
Adults age >21 y and 
a candidate for statin therapy
Yes
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)
Yes
No
Moderate-intensity statin
No
Estimate 10-y ASCVD Risk 
with Pooled Cohort Equations*
No
Yes
 
ASCVD prevention benefit of statin 
therapy may be less clear in other groups
In selected individuals, consider additional factors 
influencing ASCVD risk‡ and potential ASCVD risk 
benefits and adverse effects, drug-drug interactions, 
and patient preferences for statin treatment
No
ASCVD Statin Benefit Groups
Heart healthy lifestyle habits are the foundation of ASCVD prevention.
In individuals not receiving cholesterol-lowering drug therapy, recalculate estimated 
10-y ASCVD risk every 4-6 y in individuals aged 40-75 y without clinical ASCVD or 
diabetes and with LDL–C 70-189 mg/dL.
Yes
Estimated 10-y ASCVD risk ≥7.5%*
High-intensity statin
Age >75 y OR if not candidate for 
high-intensity statin
Moderate-intensity statin
Yes
Yes
Clinical 
ASCVD
LDL–C ≥190 
mg/dL
Diabetes
Type 1 or 2
Age 40-75 y
≥7.5% estimated
10-y ASCVD risk
and age 40-75 y
Moderate-to-high intensity statin
Definitions of High- and 
Moderate-Intensity Statin Therapy
(See Table 5)
High
Daily dose lowers 
LDL–C by appox. 
≥50%
Moderate
Daily dose lowers 
LDL–C by appox. 
30% to <50%
